Form 4: BioMarin Director Elizabeth Anderson Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Elizabeth Anderson reports the acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.
Summary
- On May 21, 2024, Elizabeth Anderson, a director at BioMarin Pharmaceutical Inc., acquired 4,720 shares of common stock in the form of restricted stock units.
- The transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Anderson directly owns 27,800 shares of BioMarin common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of restricted stock units, which can be seen as a positive but isn't necessarily a strong indicator of future performance.
Positives
- The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of restricted stock units by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2023-12-06 | Date of Power of Attorney execution. |
| 2024-05-21 | Date of transaction: Acquisition of restricted stock units. |
| 2024-05-23 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.